| Identification | Back Directory | [Name]
LG 101506 | [CAS]
331248-11-4 | [Synonyms]
LG 101506
(2E,4E,6Z)-7-[2-(2,2-Difluoroethoxy)-3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-2,4,6-octatrienoic acid | [Molecular Formula]
C25H34F2O3 | [MDL Number]
MFCD19690911 | [MOL File]
331248-11-4.mol | [Molecular Weight]
420.53 |
| Chemical Properties | Back Directory | [Boiling point ]
522.0±50.0 °C(Predicted) | [density ]
1.052±0.06 g/cm3(Predicted) | [solubility ]
DMSO:42.05(Max Conc. mg/mL);100.0(Max Conc. mM)
Ethanol:21.03(Max Conc. mg/mL);50.0(Max Conc. mM) | [pka]
4.73±0.33(Predicted) |
| Hazard Information | Back Directory | [Uses]
LG 101506 is a selective RXR modulator. It has anti-carcinogenic properties. This was demonstrated in a biological study where it was used suppress lung carcinogenesis in mice. | [in vivo]
LG101506 (10 mg/kg; in diet for 16 weeks) suppresses lung carcinogenesis in A/J mice[2]. | Animal Model: | A/J mice, lung carcinogenesis model[2] | | Dosage: | 40 mg/kg diet or approximately 10 mg/kg body weight | | Administration: | Oral, for 16 weeks | | Result: | Reduced the number of lung tumors, the average tumor burden, the size and histopathology of lung tumors. |
| Animal Model: | Male ICR mice[1] | | Dosage: | 30 mg/kg | | Administration: | Oral (Pharmacokinetic Analysis) | | Result: | In vivo evaluation of oral exposure of LG101506[1]
| Compd | Dose (mg/kg) | Oral AUC(0-6 h) (μg?h/mL) | Tmax (h) | Cmax (μg?h/mL) | | LG101506 | 30 | 2.09±0.45 | 1 | 1.2±0.28 |
Data collected in male ICR mouse using a dose formulation of the free acid in CMC/SLS/Povidone (30 mg/kg). Timepoints: 1, 3, 8 h (serial sacrifice, n=3/time point).
|
| [storage]
Store at +4°C |
|
|